An alternative therapy for drug-resistant epilepsy: transcutaneous auricular vagus nerve stimulation.

Peijing Rong; Aihua Liu; Jianguo Zhang; Yuping Wang; Anchao Yang; Liang LI; Hui Ben; Liping LI; Rupeng Liu; Wei HE; Huanguang Liu; Feng Huang; Xia LI; Peng WU; Bing Zhu

Return

An alternative therapy for drug-resistant epilepsy: transcutaneous auricular vagus nerve stimulation.

Author: Peijing RONG ¹ ; Aihua LIU ² ; Jianguo ZHANG ³ ; Yuping WANG ² ; Anchao YANG ³ ; Liang LI ¹ ; Hui BEN ¹ ; Liping LI ² ; Rupeng LIU ¹ ; Wei HE ¹ ; Huanguang LIU ³ ; Feng HUANG ¹ ; Xia LI ¹ ; Peng WU ¹ ; Bing ZHU ¹
Author Information

1. Function Laboratory, Institute of Acu-Mox, China Academy of Chinese Medical Sciences, Beijing 100700, China.
2. Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
3. Institute of Neurosurgery, Tiantan Hospital, Beijing 100050, China.
Publication Type:Journal Article
MeSH: Adolescent; Adult; Epilepsy; therapy; Female; Humans; Male; Transcutaneous Electric Nerve Stimulation; methods; Treatment Outcome; Vagus Nerve Stimulation; methods; Young Adult
From: Chinese Medical Journal 2014;127(2):300-304
CountryChina
Language:English
Abstract:
BACKGROUNDPrevious studies demonstrated that vagus nerve stimulation (VNS) is an effective therapy for drug-resistant epilepsy. Acupuncture is also used to treat epilepsy. This study was designed to examine the safety and effectiveness of transcutaneous auricular vagus nerve stimulation (ta-VNS) for patients with drug-resistant epilepsy.
METHODSA total of 50 volunteer patients with drug-resistant epilepsy were selected for a random clinical trial to observe the therapeutic effect of ta-VNS. The seizure frequency, quality of life, and severity were assessed in weeks 8, 16, and 24 of the treatment according to the percentage of seizure frequency reduction.
RESULTSIn the pilot study, 47 of the 50 epilepsy patients completed the 24-week treatment; three dropped off. After 8-week treatment, six of the 47 patients (12%) were seizure free and 12 (24%) had a reduction in seizure frequency. In week 16 of the continuous treatment, six of the 47 patients (12%) were seizure free; 17 (34%) had a reduction in seizure frequency. After 24 weeks' treatment, eight patients (16%) were seizure free; 19 (38%) had reduced seizure frequency.
CONCLUSIONSimilar to the therapeutic effect of VNS, ta-VNS can suppress epileptic seizures and is a safe, effective, economical, and widely applicable treatment option for drug-resistant epilepsy. (ChiCTR-TRC-10001023).